Skip to main content
. Author manuscript; available in PMC: 2014 Sep 11.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008040. doi: 10.1002/14651858.CD008040.pub2

Appendix 5. Summary of efficacy outcomes: migraine-associated symptoms and functional disability.

Study ID Treatment Nausea Vomitting Photophobia Phonophobia Functional disability
Any at 2h Relief at 2h Any at 2h Relief at 2h Any at 2h Relief at 2h Any at 2h Relief at 2h Severe at 2h Relief at 2h
Dexter 1985

  1. Paracetamol + metoclopramide 500/5 mg, n = 22 (18 analysed for efficacy)

  2. Placebo, n = 27 (24 analysed for efficacy)

 No data No data No data No data No data No data No data No data No data No data
Dowson 2000

  1. Paracetamol + domperidone 1000/20 mg + placebo

  2. Sumatriptan 50 mg + placebo


161 participants took medication, 120 completed both attacks and analysed for efficacy		 1. 44/120

2. 47/120 		1. 41/85

2. 34/81 		1. 6/120

2. 7/120 		1. 5/11

2. 5/12 		No data No data No data No data No data No data
Freitag 2008

  1. Paracetamol 1000 mg, n = 43

  2. Rizatriptan 10 mg, n = 43

  3. Rizatriptan + paracetamol 10/1000 mg, n = 48

  4. Placebo, n = 39

 1. 6/43

2. 8/43

3. 4/48

4. 11/39 		No data No data No data 1. 20/43

2. 11/43

3. 15/48

4. 17/39 		No data 1. 17/43

2. 7/43

3. 7/48

4. 13/39 		No data 1. 22/43

2. 16/43

3. 17/48

4. 23/39 		No data
GL/MIG/001/92

  1. Paracetamol + metoclopramide 1000/10 mg, n = 302

  2. Sumatriptan 100 mg, n = 305


Data for attack 1		 1. 48/286

2. 53/288 		1. 44/92

2. 28/81 		1. 8/286

2. 9/288 		1. 6/14

2. 5/14 		Light/noise sensitivity

1. 144/286

2. 155/288 		Light/noise sensitivity

1. 85/22

2. 979/234 		No data No data
GL/MIG/001A/92

  1. Paracetamol + metoclopramide 1000/10 mg, n = 373

  2. Sumatriptan 100 mg, n = 348


Data for attack 1		 No data No data No data No data Light/noise sensitivity

1. 208/351

2. 171/318 		Light/noise sensitivity

1. 83/291

2. 76/247 		No data No data
Hoernecke 1993

  1. Paracetamol 1000 mg

  2. Dihydroergotamine 2 mg

  3. Paracetamol + dihydroergotamine 1000/2 mg

  4. Placebo


288 participants completed all four treatments		 1. 49/288

2. 55/288

3. 41/288

4. 76/288 		1. 112/16

2. 112/18

3. 138/179

4. 101/177 		1. 12/288

2. 12/288

3. 3/288

4. 13/288 		1. 20/32

2. 29/41

3. 38/41

4. 30/43 		1. 65/288

2. 87/288

3. 49/288

4. 94/288 		1. 124/188

2. 104/191

3. 139/188

4. 94/188 		1. 59/288

2. 75/288

3. 52/288

4. 87/288 		1. 120/179

2. 112/187

3. 133/185

4. 90/177 		No data No data
Lipton 2000

  1. Paracetamol 1000 mg, n = 147

  2. Placebo, n = 142

 No sig diff between groups <2% at baseline 1. 99/146

2. 115/142 		1. 47/143

2. 27/132 		1. 99/146

2. 112/142 		1. 47/139

2. 30/130 		1. 103/147

2. 121/142 		1. 44/141

2. 21/137
MacGregor 1993

  1. Paracetamol + domperidone 1000/20 mg

  2. Paracetamol + domperidone 1000/30 mg

  3. Paracetamol 1000 mg + placebo


46 participants treated at least 1 attack, 44 treated all 3 attacks		 No data No data No data No data No data No data No data No data No data No data
Norrelund 1989

  1. Paracetamol 1000 mg

  2. Tolfenamic acid 400 mg


116 participants treated both attacks		 No data No data No data No data No data No data No data No data No data No data
Prior 2010

  1. Paracetamol 1000 mg, n = 177

  2. Placebo, n = 169

 1. 59/177

2. 78/169 		1. 42/101

2. 19/97 		No data No data 1. 141/177

2. 138/169 		1. 34/175

2. 21/159 		1. 125/177

2. 137/169 		1. 37/162

2. 20/157 		1. 138/177

2. 144/169 		1. 30/168

2. 20/164